Payment overview · 2025
General Payments
$52.11
4 reported records · 3 companies
Healthcare provider profile · identity verified
Nicholas Lemley, DO
Allopathic & Osteopathic Physicians|Family Medicine · CUERO, TX · NPI 1457885592
Verified facts
What the public records show
CMS Open Payments records show Nicholas Lemley, DO received $52.11 in general payments during 2025 across 4 reported records.
AstraZeneca Pharmaceuticals LP accounted for 54.4% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 4 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Farxiga by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $28.34 | 54.4% | 2 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $16.04 | 30.8% | 1 | 2025 |
| Organon LLC | Unresolved — no canonical attribution shown | $7.73 | 14.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $52.11 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $16.04 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $14.69 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $13.65 | 1 | 2025 |
Source payment records
|
|||||
| JADA SYSTEM Normalized: jada system |
Device | Organon LLC | $7.73 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 61 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
61 | 12 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Potassium Chloride | Potassium Chloride | 439 | 87 |
| Furosemide | Furosemide | 360 | 78 |
| Atorvastatin Calcium | Atorvastatin Calcium | 358 | 82 |
| Gabapentin | Gabapentin | 335 | 75 |
| Amlodipine Besylate | Amlodipine Besylate | 315 | 88 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 295 | 62 |
| Lisinopril | Lisinopril | 295 | 80 |
| Losartan Potassium | Losartan Potassium | 258 | 63 |
| Eliquis | Apixaban | 245 | 26 |
| Metoprolol Tartrate | Metoprolol Tartrate | 235 | 53 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 226 | 62 |
| Trazodone Hcl | Trazodone Hcl | 221 | 49 |
| Levothyroxine Sodium | Levothyroxine Sodium | 213 | 56 |
| Jardiance | Empagliflozin | 192 | 23 |
| Pantoprazole Sodium | Pantoprazole Sodium | 192 | 47 |
| Alprazolam | Alprazolam | 191 | 53 |
| Metformin Hcl | Metformin Hcl | 191 | 44 |
| Famotidine | Famotidine | 189 | 41 |
| Donepezil Hcl | Donepezil Hcl | 182 | 36 |
| Metoprolol Succinate | Metoprolol Succinate | 159 | 34 |
| Duloxetine Hcl | Duloxetine Hcl | 149 | 32 |
| Omeprazole | Omeprazole | 143 | 36 |
| Carvedilol | Carvedilol | 127 | 26 |
| Tamsulosin Hcl | Tamsulosin Hcl | 122 | 38 |
| Mounjaro | Tirzepatide | 110 | 22 |
| Clopidogrel | Clopidogrel Bisulfate | 105 | 27 |
| Ozempic | Semaglutide | 100 | 18 |
| Buspirone Hcl | Buspirone Hcl | 98 | 21 |
| Simvastatin | Simvastatin | 98 | 20 |
| Sertraline Hcl | Sertraline Hcl | 94 | 24 |
| Montelukast Sodium | Montelukast Sodium | 90 | 20 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 83 | 18 |
| Allopurinol | Allopurinol | 81 | 21 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 80 | suppressed |
| Meloxicam | Meloxicam | 79 | 22 |
| Prednisone | Prednisone | 79 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 75 | 39 |
| Tramadol Hcl | Tramadol Hcl | 69 | 32 |
| Mirtazapine | Mirtazapine | 67 | 13 |
| Pravastatin Sodium | Pravastatin Sodium | 66 | 16 |
| Azithromycin | Azithromycin | 62 | 55 |
| Fluticasone Propionate | Fluticasone Propionate | 62 | 27 |
| Spironolactone | Spironolactone | 62 | 14 |
| Escitalopram Oxalate | Escitalopram Oxalate | 61 | 12 |
| Farxiga | Dapagliflozin Propanediol | 61 | 12 |
| Warfarin Sodium | Warfarin Sodium | 58 | suppressed |
| Ondansetron Odt | Ondansetron | 57 | 20 |
| Pregabalin | Pregabalin | 57 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 56 | 22 |
| Memantine Hcl | Memantine Hcl | 56 | suppressed |
| Clonazepam | Clonazepam | 55 | 13 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 51 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 48 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 47 | 11 |
| Fluoxetine Hcl | Fluoxetine Hcl | 46 | 13 |
| Divalproex Sodium | Divalproex Sodium | 45 | 14 |
| Entresto | Sacubitril/Valsartan | 45 | suppressed |
| Vascepa | Icosapent Ethyl | 44 | suppressed |
| Cefdinir | Cefdinir | 43 | 33 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 43 | 14 |
| Paroxetine Hcl | Paroxetine Hcl | 43 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 42 | 26 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 42 | 12 |
| Sucralfate | Sucralfate | 40 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 39 | 14 |
| Ondansetron Hcl | Ondansetron Hcl | 39 | 28 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 38 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 37 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 37 | 31 |
| Methylprednisolone | Methylprednisolone | 37 | 32 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 35 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 35 | suppressed |
| Metoclopramide Hcl | Metoclopramide Hcl | 32 | suppressed |
| Nifedipine Er | Nifedipine | 32 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 32 | suppressed |
| Latanoprost | Latanoprost | 31 | suppressed |
| Torsemide | Torsemide | 31 | suppressed |
| Synthroid | Levothyroxine Sodium | 30 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 29 | suppressed |
| Atenolol | Atenolol | 29 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 29 | 16 |
| Metolazone | Metolazone | 29 | suppressed |
| Bupropion Xl | Bupropion Hcl | 28 | suppressed |
| Methocarbamol | Methocarbamol | 28 | suppressed |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 28 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 27 | 14 |
| Glimepiride | Glimepiride | 27 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 27 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 26 | 18 |
| Fluconazole | Fluconazole | 26 | 18 |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 26 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 25 | 15 |
| Januvia | Sitagliptin Phosphate | 25 | suppressed |
| Rexulti | Brexpiprazole | 25 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 24 | suppressed |
| Tradjenta | Linagliptin | 24 | suppressed |
| Cephalexin | Cephalexin | 23 | 15 |
| Glipizide | Glipizide | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 22 | suppressed |
| Irbesartan | Irbesartan | 22 | suppressed |
| Aripiprazole | Aripiprazole | 21 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 21 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 20 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 20 | 18 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 20 | 14 |
| Auvelity | Dextromethorphan Hbr/Bupropion | 18 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 18 | 18 |
| Finasteride | Finasteride | 18 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 18 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 18 | suppressed |
| Verapamil Er | Verapamil Hcl | 18 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 17 | suppressed |
| Glipizide Er | Glipizide | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Memantine Hcl Er | Memantine Hcl | 17 | suppressed |
| Np Thyroid | Thyroid,pork | 17 | suppressed |
| Rybelsus | Semaglutide | 17 | suppressed |
| Valsartan | Valsartan | 17 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Semglee (Yfgn) | Insulin Glargine-Yfgn | 16 | suppressed |
| Telmisartan | Telmisartan | 16 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 15 | suppressed |
| Ezetimibe | Ezetimibe | 15 | suppressed |
| Nortriptyline Hcl | Nortriptyline Hcl | 15 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 15 | suppressed |
| Sulfasalazine | Sulfasalazine | 15 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 14 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 14 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 14 | 13 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ibuprofen | Ibuprofen | 14 | suppressed |
| Invega Sustenna | Paliperidone Palmitate | 14 | suppressed |
| Lubiprostone | Lubiprostone | 14 | suppressed |
| Rivastigmine | Rivastigmine Tartrate | 14 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 14 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 14 | suppressed |
| Xarelto | Rivaroxaban | 14 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Clozapine | Clozapine | 13 | suppressed |
| Diphenoxylate-Atropine | Diphenoxylate Hcl/Atropine | 13 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 13 | suppressed |
| Lactulose | Lactulose | 13 | suppressed |
| Belsomra | Suvorexant | 12 | suppressed |
| Bumetanide | Bumetanide | 12 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 12 | suppressed |
| Celecoxib | Celecoxib | 12 | suppressed |
| Indapamide | Indapamide | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Pentoxifylline | Pentoxifylline | 12 | suppressed |
| Cimetidine | Cimetidine | 11 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Dutasteride | Dutasteride | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $52.11 · 4 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, FARXIGA, JADA SYSTEM, Kerendia | 1 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error